Key Highlights

  • AbbVie's $1.73 quarterly dividend has an October 15, 2026 ex-dividend date and is payable November 16 to stockholders of record.
  • The company states it has increased its dividend by more than 330 percent since its 2013 inception.
  • Second-quarter net revenues were $16.990 billion, up 10.2% reported and 9.5% operationally, with GAAP diluted EPS of $2.03.
  • Adjusted diluted EPS was $3.65, up 22.9%, including a $0.17 per share unfavorable impact from acquired IPR&D and milestones expense.

AbbVie's (NYSE:ABBV) $1.73 quarterly dividend yields 2.52% and sits beside second-quarter GAAP diluted EPS of $2.03 and adjusted diluted EPS of $3.65. The board declared it on September 10, 2026. The company announced the $1.73 quarterly rate on February 19, 2026, beginning with the payment on May 15, 2026, and states it has raised its dividend by more than 330 percent since 2013.

Dividend Program and Shareholder Returns

AbbVie's board declared a quarterly cash dividend of $1.73 per share on September 10, 2026. It is payable November 16 to stockholders of record at the close of business on October 15.

The company announced the $1.73 quarterly rate on February 19, 2026, effective with the payment on May 15, 2026. Since its 2013 inception, the company states it has increased its dividend by more than 330 percent.

About the Company

AbbVie is a biopharmaceutical company based in North Chicago, Illinois. It focuses on immunology, neuroscience and oncology, and offers products and services in its Allergan Aesthetics portfolio. The company states that its mission is to discover and deliver innovative medicines and solutions that address serious health issues.

Financial Performance Behind the Payout

AbbVie reported second-quarter worldwide net revenues of $16.990 billion versus $15.423 billion, up 10.2% reported and 9.5% operationally. Immunology net revenues were $8.786 billion, up 15.1%, with Skyrizi at $5.505 billion, Rinvoq at $2.525 billion and Humira at $756 million.

Neuroscience net revenues were $3.228 billion, up 20.3%, with Vraylar at $1.071 billion and Botox Therapeutic at $1.042 billion. Oncology net revenues were $1.650 billion, down 1.5%, and aesthetics net revenues were $1.282 billion, up 0.3%.

GAAP diluted EPS was $2.03 versus $0.52, an increase of 290.4%. Adjusted diluted EPS, a non-GAAP measure, was $3.65 versus $2.97, up 22.9%. The GAAP gross margin ratio was 74.7% and the adjusted ratio was 84.7%. The GAAP operating margin ratio was 37.9% and the adjusted ratio was 48.3%. Net interest expense was $679 million.

The Apogee Therapeutics Acquisition in Guidance

On July 31, 2026 AbbVie announced a definitive agreement to acquire Apogee Therapeutics, valuing Apogee at a total equity value of approximately $10.9 billion. The company described the transaction as proposed, with a third-quarter 2026 closing target. It includes zumilokibart (APG777), a late-stage IL-13 antibody for atopic dermatitis.

The updated guidance includes a $0.14 per share dilutive impact in 2026, partly offset by $0.10 of overperformance. It also includes an unfavorable $0.58 per share impact from acquired IPR&D and milestones expense incurred through the second quarter, and excludes any such expense beyond that quarter.

Outlook

AbbVie's 2026 adjusted diluted EPS guidance is $13.87 to $14.07, updated from $13.91 to $14.11, a change of $0.04 at the midpoint. The company states the guidance includes the Apogee Therapeutics dilution and excludes acquired IPR&D and milestones that may be incurred beyond the second quarter of 2026.